NCT07241754Not yet recruiting
Predictors of Drug Resistant Epilepsy Among Pediatric Patients
Predictors of Anti-seizure Medication Resistance in Pediatric Epilepsy
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
1. This study aims to determine the main predictors of drug resistance in pediatric epilepsy by examining clinical data, EEG abnormalities, and neuroimaging results, in order to support early identification of resistant cases and improve treatment strategies . 2. Early introduction of new lines of treatment in case of refractory epilepsy as : Ketogenic diet , Rituximab and solumedrol
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 29 Dec 2025
- Primary completion date
- 29 Dec 2026
- Lead sponsor
- Assiut University
- Diseases
- Epilepsy
- NCT number
- NCT07241754
What you commit to
- Study type: Observational
- Planned participants: 200
- From 29 Dec 2025 to the primary completion date, 29 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients controlled on antiseizure medications
Other illness
- Patients with acute symptomatic seizures (e.g., febrile seizures, metabolic or infectious causes) or pseudo refractory epilepsy (e .g. syncope or uncorrect ASMs)
Age
- Children younger than 1 year or older than 18 years.
Other
- Refusal of parents or guardians to participate in the study
Who the study is looking for
- Children aged 1-18 years with a confirmed diagnosis of epilepsy.
- Both males and females will be included.
Age in the registry: 1 year to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.